Answers are grounded in this paper and cite their sources.
Ginger scientifically referred to as Zingiber officinale, is a popular medicinal and culinary herb known for its therapeutic applications in traditional medicine in Nigeria. Despite widespread studies on ginger, there is still a lack of comprehensive scoping reviews that integrate its bioactive constituents, molecular mechanisms, therapeutic potential, and current research limits across experimental and clinical studies. This scoping review aimed to evaluate the major bioactive constituents and medicinal properties of Z. officinale using evidence from peer-reviewed scientific literature. Relevant studies were obtained from PubMed, Scopus, Web of Science, and Google Scholar using PRISMA-ScR criteria. Articles covering phytochemistry, pharmacological activity, mechanisms of action, and experimental or clinical studies of ginger were included and thematically summarized. The review identified several key bioactive compounds in ginger, including 6-gingerol, 6-shogaol, 6-paradol, zingerone, volatile oils like zingiberene, and different diarylheptanoids that are responsible for ginger's antioxidant, anti-inflammatory, antimicrobial, hepatoprotective, cardioprotective, neuroprotective, antidiabetic, lipid-lowering, antiemetic, and anticancer properties. Among them, 6-gingerol and 6-shogaol were identified as the main active compounds due to their strong antioxidant and anti-inflammatory effects. Despite promising findings, majority of documented pharmacological effects were based on in vitro and animal studies, while clinical evidence remains limited and sometimes inconsistent. Additionally, challenges like poor bioavailability, inconsistency in dosage and insufficient long-term safety data continues to impede clinical translation. Zingiber officinale has considerable therapeutic potential driven by diverse bioactive compounds and molecular mechanisms. However, further well-designed clinical and translational studies are necessary to validate its therapeutic efficacy, safety, dosage uniformity, and pharmaceutical applicability in humans.
No takes yet. Share an insight, caveat, or question.
Okom et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: